pyrazines has been researched along with Parkinsonian Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, ZH; Li, YN; Peng, Y; Qu, ZY; Xu, ML; Zhang, Q; Zhao, H | 1 |
| Chen, L; Cheng, L; Liu, H; Liu, X; Ren, Z; Wang, S; Wei, X; Wu, Y; Yuan, Z | 1 |
| Drabczyńska, A; Filipek, B; Kieć-Kononowicz, K; Müller, CE; Sapa, J; Zygmunt, M | 1 |
3 other study(ies) available for pyrazines and Parkinsonian Disorders
| Article | Year |
|---|---|
Tetramethylpyrazine alleviated cytokine synthesis and dopamine deficit and improved motor dysfunction in the mice model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Benzofurans; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; In Vitro Techniques; Male; Mice; Neurons; Parkinsonian Disorders; Patch-Clamp Techniques; Postural Balance; Psychomotor Performance; Pyrazines; Quinolines; Vasodilator Agents | 2014 |
Tetramethylpyrazine Analogue CXC195 Protects Against Dopaminergic Neuronal Apoptosis via Activation of PI3K/Akt/GSK3β Signaling Pathway in 6-OHDA-Induced Parkinson's Disease Mice.
Topics: Animals; Apoptosis; Dopaminergic Neurons; Dose-Response Relationship, Drug; Glycogen Synthase Kinase 3 beta; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazines; Random Allocation; Signal Transduction | 2017 |
Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Male; Mice; Parkinsonian Disorders; Purines; Pyrazines; Pyrimidines; Receptor, Adenosine A2A | 2011 |